Abciximab: Difference between revisions
Jump to navigation
Jump to search
Matt Pijoan (talk | contribs) m (Protected "Abciximab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
Gerald Chi (talk | contribs) m (Changed protection level for "Abciximab" ([Edit=Allow only autoconfirmed users] (expires 19:17, 12 February 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 19:17, 12 February 2014 (UTC)))) |
(No difference)
| |
Revision as of 19:17, 29 January 2014
Synonyms: 7E3 antibody, ReoPro, abciximab, c7E3
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Dosing and Administration
The recommended dosage of Abciximab in adults is a 0.25 mg/kg intravenous bolus administered 10-60 minutes before the start of PCI, followed by a continuous intravenous infusion of 0.125 µg/kg/min (to a maximum of 10 µg/min) for 12 hours.
Patients with unstable angina not responding to conventional medical therapy and who are planned to undergo PCI within 24 hours may be treated with an Abciximab 0.25 mg/kg intravenous bolus followed by an 18- to 24-hour intravenous infusion of 10 µg/min, concluding one hour after the PCI.
Indications
Contraindications
Side effects
Drug interactions
Precautions
Instructions for administration
Pharmacokinetics
How supplied
Patient information
FDA package label
Detailed information
Official website
Adapted from the FDA Package Insert.